DNA 진단 시장 규모, 점유율, 동향 분석 보고서 : 기술별, 용도별, 지역별, 부문별 예측(2025-2030년)

DNA Diagnostics Market Size, Share & Trends Analysis Report By Technology (PCR-based Diagnostics, NGS DNA Diagnosis), By Application (Cancer Genetics Tests, Infectious Diseases DNA Testing), By Region, And Segment Forecasts, 2025 - 2030

US $ 5,950 ￦ 8,530,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950 ￦ 9,964,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950 ￦ 12,831,000

Printable PDF & Excel (Enterprise License)

보고서 구매 기업 및 그 자회사, 관계사가 사용할 수 있는 라이선스이며, PDF 및 엑셀 텍스트 등의 복사 및 붙여넣기, 인쇄가 가능합니다.

한글목차

DNA 진단 시장 성장과 동향

Grand View Research, Inc.의 최신 보고서에 따르면, 세계 DNA 진단 시장 규모는 2030년 141억 4,000만 달러에 달할 것으로 예상되며, 2025-2030년까지 연평균 8.7%의 성장률을 기록할 것으로 전망됩니다. 이 시장의 성장은 유전체 시퀀싱의 발전과 맞춤형 DNA 수준 진단 애플리케이션의 개발로 인한 것입니다. 또한, 정부가 후원하는 특허 연구 이니셔티브와 자금 지원 프로젝트의 증가는 시장 수요를 더욱 촉진할 것으로 예상됩니다. 예를 들어, 영국 정부는 2022년 12월 첨단 유전체 연구 개발 및 창출을 위해 2억 2,940만 달러(한화 약 1,750만 원)의 자금을 지원한다고 발표했습니다.

시장 성장은 유전체 프로파일링을 위한 새로운 기술의 채택으로 인해 크게 촉진될 것입니다. 또한, 맞춤형 의료를 위한 치료 및 진단을 위해 DNA 프로토타이핑에 의존하는 만성 종양 및 감염성 질환의 발병률이 증가함에 따라 DNA 진단/검사 연구에 대한 수요는 예측 기간 동안 크게 증가할 것으로 예상됩니다. 또한, DNA 진단/검사에 대한 수요 증가는 산전 검사 및 체외수정에 대한 수요 증가로 인해 시장에 긍정적인 성장 전망을 가져올 것으로 예상되며, 2022년 9월 Eurofins Genoma는 배아를 포함하지 않는 비침습적 착상 전 스크리닝 검사인 niPGT-A의 출시를 발표했습니다.

DNA 진단은 차세대 염기서열 분석(NGS)과 같은 기술을 통해 종양 유전체를 포괄적으로 분석할 수 있으며, NGS는 여러 유전자의 동시 염기서열 분석이 가능하여 종양에 존재하는 유전적 변화를 상세히 설명할 수 있습니다. 과학자와 임상의는 종양 유전체를 정상 조직 DNA와 비교하여 암세포 특유의 돌연변이, 사본 수 변동, 구조적 재배열을 식별할 수 있습니다. 2022년 6월, DNA 시퀀싱 및 어레이 기반 기술 제공업체인 일루미나는 종양 유전체에 대한 더 깊은 인사이트를 얻기 위해 머크와 협력하기로 했습니다. 종양 유전체에 대한 더 깊은 인사이트를 얻기 위해 머크와 공동으로 개발한 연구 테스트를 발표할 예정입니다.

C형 간염 바이러스(HCV)는 전 세계적으로 수백만 명이 앓고 있는 세계 보건 문제이며, HCV를 적시에 정확하게 진단하는 것은 효과적인 치료와 추가 감염을 예방하는 데 필수적입니다. 이러한 상황에서 DNA 진단은 HCV 감염을 감지하고 관리할 수 있는 강력한 도구로 부상하고 있으며, 2022년 7월 로슈는 C형 간염 바이러스 퇴치를 위한 세계 노력을 지원하기 위해 획기적인 항원-항체 이중 진단 테스트인 엘렉시스 HCV 듀오(Elecsys HCV Duo)를 출시하였습니다.

DNA 진단약 시장 보고서 하이라이트

• PCR 기반 진단 부문은 2024년 49.40%의 가장 큰 점유율을 차지했습니다. 이 부문의 우위는 혁신적인 PCR 기반 진단을 도입하는 주요 기업의 증가로 인해 시장에서 널리 사용되고 제품의 가용성이 높아졌기 때문입니다.
• NGS DNA 진단은 종합적인 유전자 분석을 가능하게 하는 고성능 시퀀싱 기술의 발전으로 인해 예측 기간 동안 13.9%의 CAGR로 급성장할 것으로 예상됩니다.
• 암 유전자 검사 부문은 2024년 29.80%의 가장 큰 점유율을 차지했으며, DNA 시퀀싱 기술은 다양한 암종과 유전성 질환을 식별하고 특성화하는 데 점점 더 많이 활용되고 있습니다.
• 북미 DNA 진단 시장은 2024년 전체 세계 시장을 지배하며 42.72%의 매출 점유율을 차지했습니다.

목차

제1장 조사 방법과 범위

제2장 주요 요약

제3장 DNA 진단 시장 변수, 동향, 범위

• 시장 계통 전망
  • 상부 시장 전망
  • 관련/부수 시장 전망
• 시장 역학
  • 시장 성장 촉진요인 분석
  • 시장 성장 억제요인 분석
• DNA 진단 시장 분석 툴
  • 산업 분석 - Porter's Five Forces 분석
  • PESTEL 분석

제4장 DNA 진단 시장 : 기술별, 추정·동향 분석

• 부문 대시보드
• DNA 진단 시장 : 기술 변동 분석
• 기술 전망에 의한 DNA 진단 시장
• 2018-2030년 시장 규모와 예측과 동향 분석
• PCR 기반 진단
• NGS DNA 진단
• ISH(In Situ Hybridization) 진단
• 마이크로어레이 기반 진단
• 기타

제5장 DNA 진단 시장 : 용도별, 추정·동향 분석

• 부문 대시보드
• DNA 진단 시장 : 용도 변동 분석
• DNA 진단 시장 용도별 전망
• 2018-2030년 시장 규모와 예측과 동향 분석
• 암 유전자 검사
• 감염증 DNA 검사
  • HBV 진단
  • 결핵 진단
  • CT/NG 진단
  • HPV 진단
  • MRSA 진단
  • 기타
• 신생아 유전자 스크리닝
• 착상전 진단과 생식 진단
• 비감염성 질환 DNA 검사
  • 심혈관질환
  • CNS와 PNS 관련
  • 골격, 결합 조직, 외배엽, 진피 DNA 검사
  • 폐, 신장, 간, 소화기 관련
  • 감각 질환
• 출생전 DNA 캐리어 스크리닝
• 약물유전체학/약제 대사
• 혈액학과 면역학/신원 진단과 법의학
• 기타

제6장 DNA 진단 시장 : 지역별, 추정·동향 분석

• 지역 대시보드
• 지역 DNA 진단 시장 변동 분석
• DNA 진단 시장 : 기술, 바이오소재, 최종 용도에 의한 지역 추정·동향 분석
• 2018-2030년 시장 규모와 예측과 동향 분석
• 북미
  • 미국
  • 캐나다
  • 유럽
  • 영국
  • 독일
  • 프랑스
  • 이탈리아
  • 스페인
  • 덴마크
  • 노르웨이
  • 스웨덴
• 아시아태평양
  • 일본
  • 중국
  • 인도
  • 한국
  • 호주
  • 태국
• 라틴아메리카
  • 아르헨티나
  • 멕시코
• 중동 및 아프리카
  • 남아프리카공화국
  • 사우디아라비아
  • 아랍에미리트
  • 쿠웨이트

제7장 경쟁 구도

• 시장 진출 기업 분류
• 기업 분류
• 전략 매핑
  • 신제품 발매
  • 파트너십
  • 취득
  • 협업
• 주요 기업의 시장 점유율 분석, 2024년
• 주요 기업 개요
  • Abbott
  • F. Hoffmann-La Roche Ltd.
  • QIAGEN
  • Bio-Rad Laboratories, Inc.
  • Thermo Fisher Scientific, Inc.
  • Illumina, Inc.
  • Hologic, Inc.
  • Agilent Technologies Inc.
  • Siemens Healthineers AG
  • Danaher Corporation

ksm

영문 목차

영문목차

DNA Diagnostics Market Growth & Trends:

The global DNA diagnostics market size is expected to reach a value of USD 14.14 billion in 2030 and is projected to grow at a CAGR of 8.7% from 2025 to 2030, according to a new report by Grand View Research, Inc. The growth of the market is due to advancements in genome sequencing and the development of personalized DNA-level diagnostic applications. In addition, the rising number of government-sponsored patented research initiatives and funded projects are anticipated to further drive demand in the market. For instance, in December 2022, the UK government announced a funding of USD 229.4 (£175) million for the development and creation of advanced genomic research.

The market growth is highly driven by the introduction of novel technologies for genome profiling. Moreover, with the increasing incidence of chronic oncology and infectious diseases that rely on DNA prototyping for treatment and diagnosis through personalized medicine, the demand for DNA diagnostics/testing-based research is anticipated to increase significantly over the forecast period. Furthermore, the increasing demand for DNA diagnostics/testing is driven by the rising demand for prenatal testing, and in-vitro fertilization is expected to provide positive growth prospects to the market. In September 2022, Eurofins Genoma announced the launch of niPGT-A, an embryo-free, non-invasive preimplantation screening test.

DNA diagnostics enables the comprehensive analysis of tumor genomes through techniques such as next-generation sequencing (NGS). NGS allows for the simultaneous sequencing of multiple genes, providing a detailed view of the genetic alterations present in the tumor. By comparing the tumor genome with normal tissue DNA, scientists and clinicians can identify specific mutations, copy number variations, and structural rearrangements unique to the cancer cells. In June 2022, Illumina, a DNA sequencing and array-based technology provider, introduces a research test developed in collaboration with Merck, aimed at unlocking deeper insights into the tumor genome.

Hepatitis C virus (HCV) is a global health concern, affecting millions of people worldwide. Accurate and timely diagnosis of HCV is crucial for effective treatment and prevention of further transmission. In this context, DNA diagnostics has emerged as a powerful tool for detecting and managing HCV infections. In July 2022, Roche introduced a groundbreaking dual antigen and antibody diagnostic test Elecsys HCV Duo, to aid the global efforts in eradicating the hepatitis C virus.

DNA Diagnostics Market Report Highlights:

• The PCR-based diagnostics segment held the largest share of 49.40% in 2024, the dominance of this segment can be attributed to the widespread market usage and the increase in product availability due to the rising number of key players introducing innovative PCR-based diagnostics
• NGS DNA diagnosis is projected to grow fastest CAGR of 13.9% over the forecast period owing to advancements in high-throughput sequencing technologies that enable comprehensive genetic analyses.
• Cancer genetics tests segment held the largest share of 29.80% in 2024. DNA sequencing technologies are increasingly utilized to identify and characterize various cancer types and genetic disorders.
• North America DNA diagnostics market dominated the overall global market and accounted for the 42.72% revenue share in 2024.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.2. Segment Definitions
  • 1.2.1. Technology
  • 1.2.2. Application
  • 1.2.3. Regional Scope
  • 1.2.4. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Technology outlook
  • 2.2.2. Application outlook
• 2.3. Regional outlook
• 2.4. Competitive Insights

Chapter 3. DNA Diagnostics Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
  • 3.2.2. Market Restraint Analysis
• 3.3. DNA Diagnostics Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Bargaining power of suppliers
    • 3.3.1.2. Bargaining power of buyers
    • 3.3.1.3. Threat of substitutes
    • 3.3.1.4. Threat of new entrants
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Economic landscape
    • 3.3.2.3. Social landscape
    • 3.3.2.4. Technological landscape
    • 3.3.2.5. Environmental landscape
    • 3.3.2.6. Legal landscape

Chapter 4. DNA Diagnostics Market: Technology Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. DNA Diagnostics Market: Technology Movement Analysis
• 4.3. DNA Diagnostics Market by Technology Outlook (USD Million)
• 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
• 4.5. PCR-based Diagnostics
  • 4.5.1. PCR-based Diagnostics Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.6. NGS DNA Diagnosis
  • 4.6.1. NGS DNA Diagnosis Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.7. In-Situ Hybridization Diagnostics
  • 4.7.1. In-Situ Hybridization Diagnostics Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.8. Microarrays-based Diagnostics
  • 4.8.1. Microarrays-based Diagnostics Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.9. Other Technologies
  • 4.9.1. In Other Technologies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. DNA Diagnostics Market: Application Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. DNA Diagnostics Market: Application Movement Analysis
• 5.3. DNA Diagnostics Market by Application Outlook (USD Million)
• 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
• 5.5. Cancer Genetics Tests
  • 5.5.1. Cancer Genetics Tests Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.6. Infectious Diseases DNA Testing
  • 5.6.1. Infectious Diseases DNA Testing Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.6.2. HBV Diagnostic
    • 5.6.2.1. HBV Diagnostic Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.6.3. TB Diagnostic
    • 5.6.3.1. TB Diagnostic Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.6.4. CT/NG Diagnostic
    • 5.6.4.1. CT/NG Diagnostic Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.6.5. HPV Diagnostic
    • 5.6.5.1. HPV Diagnostic Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.6.6. MRSA Diagnostic
    • 5.6.6.1. MRSA Diagnostic Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.6.7. Others
    • 5.6.7.1. Others Diagnostic Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.7. Newborn Genetic Screening
  • 5.7.1. Newborn Genetic Screening Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.8. Preimplantation & Reproductive Diagnosis
  • 5.8.1. Preimplantation & Reproductive Diagnosis Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.9. Non-Infectious Diseases DNA Testing
  • 5.9.1. Non-Infectious Diseases DNA Testing Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.9.2. Cardiovascular Diseases
    • 5.9.2.1. Cardiovascular Diseases Diagnostic Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.9.3. CNS & PNS Related
    • 5.9.3.1. CNS & PNS Related Diagnostic Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.9.4. Skeletal, Connective, Ectodermal & Dermal DNA Testing
    • 5.9.4.1. Skeletal, Connective, Ectodermal & Dermal DNA Testing Diagnostic Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.9.5. Lung, Kidney, Liver & GT Related
    • 5.9.5.1. Lung, Kidney, Liver & GT Related Diagnostic Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.9.6. Sensory Diseases
    • 5.9.6.1. Sensory Diseases Diagnostic Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.10. Prenatal DNA Carrier Screening
  • 5.10.1. Prenatal DNA Carrier Screening Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.11. Pharmacogenomics/Drug Metabolism
  • 5.11.1. Pharmacogenomics/Drug Metabolism Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.12. Hematology & Immunology/Identity Diagnostics & Forensics
  • 5.12.1. Hematology & Immunology/Identity Diagnostics & Forensics Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.13. Others
  • 5.13.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. DNA Diagnostics Market: Regional Estimates & Trend Analysis

• 6.1. Regional Dashboard
• 6.2. Regional DNA Diagnostics Market movement analysis
• 6.3. DNA Diagnostics Market: Regional Estimates & Trend Analysis by Technology, Biomaterial & End-use
• 6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
• 6.5. North America
  • 6.5.1. North America DNA Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5.2. U.S.
    • 6.5.2.1. U.S. DNA Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.2.2. Key Country Dynamics
    • 6.5.2.3. Regulatory Framework
    • 6.5.2.4. Reimbursement Scenario
    • 6.5.2.5. Competitive Scenario
  • 6.5.3. Canada
    • 6.5.3.1. Canada DNA Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.3.2. Key Country Dynamics
    • 6.5.3.3. Regulatory Framework
    • 6.5.3.4. Reimbursement Scenario
    • 6.5.3.5. Competitive Scenario
  • 6.5.4. Europe
  • 6.5.5. Europe DNA Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5.6. UK
    • 6.5.6.1. UK DNA Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.6.2. Key Country Dynamics
    • 6.5.6.3. Regulatory Framework
    • 6.5.6.4. Reimbursement Scenario
    • 6.5.6.5. Competitive Scenario
  • 6.5.7. Germany
    • 6.5.7.1. Germany DNA Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.7.2. Key Country Dynamics
    • 6.5.7.3. Regulatory Framework
    • 6.5.7.4. Reimbursement Scenario
    • 6.5.7.5. Competitive Scenario
  • 6.5.8. France
    • 6.5.8.1. France DNA Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.8.2. Key Country Dynamics
    • 6.5.8.3. Regulatory Framework
    • 6.5.8.4. Reimbursement Scenario
    • 6.5.8.5. Competitive Scenario
  • 6.5.9. Italy
    • 6.5.9.1. Italy DNA Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.9.2. Key Country Dynamics
    • 6.5.9.3. Regulatory Framework
    • 6.5.9.4. Reimbursement Scenario
    • 6.5.9.5. Competitive Scenario
  • 6.5.10. Spain
    • 6.5.10.1. Spain DNA Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.10.2. Key Country Dynamics
    • 6.5.10.3. Regulatory Framework
    • 6.5.10.4. Reimbursement Scenario
    • 6.5.10.5. Competitive Scenario
  • 6.5.11. Denmark
    • 6.5.11.1. Denmark DNA Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.11.2. Key Country Dynamics
    • 6.5.11.3. Regulatory Framework
    • 6.5.11.4. Reimbursement Scenario
    • 6.5.11.5. Competitive Scenario
  • 6.5.12. Norway
    • 6.5.12.1. Norway DNA Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.12.2. Key Country Dynamics
    • 6.5.12.3. Regulatory Framework
    • 6.5.12.4. Reimbursement Scenario
    • 6.5.12.5. Competitive Scenario
  • 6.5.13. Sweden
    • 6.5.13.1. Sweden DNA Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.13.2. Key Country Dynamics
    • 6.5.13.3. Regulatory Framework
    • 6.5.13.4. Reimbursement Scenario
    • 6.5.13.5. Competitive Scenario
• 6.6. Asia Pacific
  • 6.6.1. Asia Pacific DNA Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6.2. Japan
    • 6.6.2.1. Japan DNA Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.2.2. Key Country Dynamics
    • 6.6.2.3. Regulatory Framework
    • 6.6.2.4. Reimbursement Scenario
    • 6.6.2.5. Competitive Scenario
  • 6.6.3. China
    • 6.6.3.1. China DNA Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.3.2. Key Country Dynamics
    • 6.6.3.3. Regulatory Framework
    • 6.6.3.4. Reimbursement Scenario
    • 6.6.3.5. Competitive Scenario
  • 6.6.4. India
    • 6.6.4.1. India DNA Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.4.2. Key Country Dynamics
    • 6.6.4.3. Regulatory Framework
    • 6.6.4.4. Reimbursement Scenario
    • 6.6.4.5. Competitive Scenario
  • 6.6.5. South Korea
    • 6.6.5.1. South Korea DNA Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.5.2. Key Country Dynamics
    • 6.6.5.3. Regulatory Framework
    • 6.6.5.4. Reimbursement Scenario
    • 6.6.5.5. Competitive Scenario
  • 6.6.6. Australia
    • 6.6.6.1. Australia DNA Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.6.2. Key Country Dynamics
    • 6.6.6.3. Regulatory Framework
    • 6.6.6.4. Reimbursement Scenario
    • 6.6.6.5. Competitive Scenario
  • 6.6.7. Thailand
    • 6.6.7.1. Thailand DNA Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.7.2. Key Country Dynamics
    • 6.6.7.3. Regulatory Framework
    • 6.6.7.4. Reimbursement Scenario
    • 6.6.7.5. Competitive Scenario
• 6.7. Latin America
  • 6.7.1. Latin America DNA Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.7.2.1. Brazil DNA Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.7.2.2. Key Country Dynamics
    • 6.7.2.3. Regulatory Framework
    • 6.7.2.4. Reimbursement Scenario
    • 6.7.2.5. Competitive Scenario
  • 6.7.3. Argentina
    • 6.7.3.1. Argentina DNA Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.7.3.2. Key Country Dynamics
    • 6.7.3.3. Regulatory Framework
    • 6.7.3.4. Reimbursement Scenario
    • 6.7.3.5. Competitive Scenario
  • 6.7.4. Mexico
    • 6.7.4.1. Mexico DNA Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.7.4.2. Key Country Dynamics
    • 6.7.4.3. Regulatory Framework
    • 6.7.4.4. Reimbursement Scenario
    • 6.7.4.5. Competitive Scenario
• 6.8. Middle East & Africa
  • 6.8.1. Middle East & Africa DNA Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.8.2. South Africa
    • 6.8.2.1. South Africa DNA Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.8.2.2. Key Country Dynamics
    • 6.8.2.3. Regulatory Framework
    • 6.8.2.4. Reimbursement Scenario
    • 6.8.2.5. Competitive Scenario
  • 6.8.3. Saudi Arabia
    • 6.8.3.1. Saudi Arabia DNA Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.8.3.2. Key Country Dynamics
    • 6.8.3.3. Regulatory Framework
    • 6.8.3.4. Reimbursement Scenario
    • 6.8.3.5. Competitive Scenario
  • 6.8.4. UAE
    • 6.8.4.1. UAE DNA Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.8.4.2. Key Country Dynamics
    • 6.8.4.3. Regulatory Framework
    • 6.8.4.4. Reimbursement Scenario
    • 6.8.4.5. Competitive Scenario
  • 6.8.5. Kuwait
    • 6.8.5.1. Kuwait DNA Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.8.5.2. Key Country Dynamics
    • 6.8.5.3. Regulatory Framework
    • 6.8.5.4. Reimbursement Scenario
    • 6.8.5.5. Competitive Scenario

Chapter 7. Competitive Landscape

• 7.1. Market Participant Categorization
• 7.2. Company Categorization
• 7.3. Strategy Mapping
  • 7.3.1. NEW PRODUCT LAUNCH
  • 7.3.2. PARTNERSHIPS
  • 7.3.3. ACQUISITION
  • 7.3.4. COLLABORATION
• 7.4. Key Company Market Share Analysis, 2024
• 7.5. Key Company Profiles
  • 7.5.1. Abbott
    • 7.5.1.1. Company overview
    • 7.5.1.2. Financial performance
    • 7.5.1.3. Technology benchmarking
    • 7.5.1.4. Strategic initiatives
  • 7.5.2. F. Hoffmann-La Roche Ltd.
    • 7.5.2.1. Company overview
    • 7.5.2.2. Financial performance
    • 7.5.2.3. Technology benchmarking
    • 7.5.2.4. Strategic initiatives
  • 7.5.3. QIAGEN
    • 7.5.3.1. Company overview
    • 7.5.3.2. Financial performance
    • 7.5.3.3. Technology benchmarking
    • 7.5.3.4. Strategic initiatives
  • 7.5.4. Bio-Rad Laboratories, Inc.
    • 7.5.4.1. Company overview
    • 7.5.4.2. Financial performance
    • 7.5.4.3. Technology benchmarking
    • 7.5.4.4. Strategic initiatives
  • 7.5.5. Thermo Fisher Scientific, Inc.
    • 7.5.5.1. Company overview
    • 7.5.5.2. Financial performance
    • 7.5.5.3. Technology benchmarking
    • 7.5.5.4. Strategic initiatives
  • 7.5.6. Illumina, Inc.
    • 7.5.6.1. Company overview
    • 7.5.6.2. Financial performance
    • 7.5.6.3. Technology benchmarking
    • 7.5.6.4. Strategic initiatives
  • 7.5.7. Hologic, Inc.
    • 7.5.7.1. Company overview
    • 7.5.7.2. Financial performance
    • 7.5.7.3. Technology benchmarking
    • 7.5.7.4. Strategic initiatives
  • 7.5.8. Agilent Technologies Inc.
    • 7.5.8.1. Company overview
    • 7.5.8.2. Financial performance
    • 7.5.8.3. Technology benchmarking
    • 7.5.8.4. Strategic initiatives
  • 7.5.9. Siemens Healthineers AG
    • 7.5.9.1. Company overview
    • 7.5.9.2. Financial performance
    • 7.5.9.3. Technology benchmarking
    • 7.5.9.4. Strategic initiatives
  • 7.5.10. Danaher Corporation
    • 7.5.10.1. Company overview
    • 7.5.10.2. Financial performance
    • 7.5.10.3. Technology benchmarking
    • 7.5.10.4. Strategic initiatives

관련자료